2013 Healthcare Pharmaceutical products 
European Pharmaceutical Review
JANUARY 16, 2023
presented their pathway for regulatory approval to the FDA Vaccines and Related Biological Products Advisory Committee for a faecal microbiota-based live biotherapeutic to treat recurrent Clostridioides difficile infection, which is a major Healthcare Acquired Infection (HAI). For example, in September 2022, the company Rebiotix, Inc.
European Pharmaceutical Review
DECEMBER 19, 2023
TRS 953 – Annex 2, Appendix 1: Stability testing of active pharmaceutical ingredients and finished pharmaceutical products: Stability conditions for WHO Member States by Region. It has potential to be applied simply and directly to most existing commercial vaccines. 2011;29:7122–7124. Sharma D, Khamar S, Cullen A, et al.
Expert insights. Personalized for you.
128 
Let's personalize your content